PathAI is the world’s leading provider of AI-powered technology for the pathology laboratory.
Andrew H. Beck, MD PhD
Co-Founder & CEO
Andy earned his MD from Brown Medical School and completed residency and fellowship training in Anatomic Pathology and Molecular Genetic Pathology from Stanford University. He completed a PhD in Biomedical Informatics from Stanford University, where he developed one of the first machine-learning based systems for cancer pathology. He's been certified by the American Board of Pathology in Anatomic Pathology and Molecular Genetic Pathology. Prior to co-founding PathAI, he was on the faculty of Harvard Medical School in the Department of Pathology at Beth Israel Deaconess Medical Center. He has published over 110 papers in the fields of cancer biology, cancer pathology, and biomedical informatics.
Aditya Khosla, PhD
Co-Founder & CTO
Aditya recently completed his PhD in machine learning and computer vision at MIT. He completed his MS at Stanford in 2011 and BS at Caltech in 2009. In his research he developed new methods for an array of applications in computer vision, including eye-tracking, prediction of image memorability, and visualization of deep networks. He is the recipient of a Facebook Fellowship and his work has been widely covered by various media outlets including BBC, The New York Times and The Washington Post. He has published over 30 papers in the fields of deep learning, computer vision and neuroscience.
Vice President of Regulatory Affairs, Clinical Affairs and Strategic Business Development
Board Members & Advisors
CEO, Lapidx Research
CEO, Vertex Pharmaceuticals
CEO, Aegis Science Corporation
Director, Surgical Pathology & Professor, Pathology, Johns Hopkins University
Chair, Department of Anatomic Pathology, Cleveland Clinic
Serial Entrepreneur, Advisor, and Investor
Director, Anatomical Pathology & Vice-Chief, Pathology, Rhode Island & The Miriam Hospitals, Professor, Pathology, Brown University
Engineering Manager, Facebook
Professor, Pathology, Harvard Medical School & Chief of Breast Oncologic Pathology, Dana-Farber/Brigham and Women’s Cancer Center